Evidence map›Paper›PMID 36117385›Full record

ArticlePhysiological reports2022

An iPS-derived in vitro model of human atrial conduction.

Sherri M Biendarra-Tiegs, Sergey Yechikov, Bhupinder Shergill, Brittany Brumback, Kentaro Takahashi, Venktesh S Shirure, Ruth Estelle Gonzalez, Laura Houshmand, Denise Zhong, Kuo-Chan Weng and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Physiological reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sherri M Biendarra-TiegsDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Sergey YechikovDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Bhupinder ShergillDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Brittany BrumbackDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA.ORCID 0000-0002-8376-4959
Kentaro TakahashiDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Venktesh S ShirureDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Ruth Estelle GonzalezDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Laura HoushmandDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Denise ZhongDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.
Kuo-Chan WengDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA.
Jon SilvaDepartment of Biomedical Engineering, Washington University in St. Louis, St. Louis, Missouri, USA.
Timothy W SmithDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Stacey L RentschlerDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Steven C GeorgeDepartment of Biomedical Engineering, University of California, Davis, Davis, California, USA.ORCID 0000-0003-2263-1914
University of California, Davis · USWashington University in St. Louis · US

Funding

Training Program In Basic & Translational Cardiovascular ScienceT32HL086350 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI Martin Cadeiras, David A. Liem · 2008 to 2026
$7.1M
Pediatric Cardiovascular and Pulmonary Research Training Program.T32HL125241 · NHLBI · WASHINGTON UNIVERSITY · PI Juliane Bubeck Wardenburg, Kory J. Lavine · 2015 to 2026
$4.1M
A 3D IN VITRO DISEASE MODEL OF ATRIAL CONDUCTIONUH3HL141800 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CURIEL, DAVID TERRY, GEORGE, STEVEN CARL · 2019 to 2021
$4.0M
NHLBI NIH HHS T32 HL086350NHLBI NIH HHS T32 HL125241NHLBI NIH HHS UH3 HL141800NIH HHS T32 HL086350NIH HHS T32 HL125241NIH HHS UH3 HL141800
6 · The paper itself

Abstract

Atrial fibrillation (AF) is the most common arrhythmia in the United States, affecting approximately 1 in 10 adults, and its prevalence is expected to rise as the population ages. Treatment options for AF are limited; moreover, the development of new treatments is hindered by limited (1) knowledge regarding human atrial electrophysiological endpoints (e.g., conduction velocity [CV]) and (2) accurate experimental models. Here, we measured the CV and refractory period, and subsequently calculated the conduction wavelength, in vivo (four subjects with AF and four controls), and ex vivo (atrial slices from human hearts). Then, we created an in vitro model of human atrial conduction using induced pluripotent stem (iPS) cells. This model consisted of iPS-derived human atrial cardiomyocytes plated onto a micropatterned linear 1D spiral design of Matrigel. The CV (34-41 cm/s) of the in vitro model was nearly five times faster than 2D controls (7-9 cm/s) and similar to in vivo (40-64 cm/s) and ex vivo (28-51 cm/s) measurements. Our iPS-derived in vitro model recapitulates key features of in vivo atrial conduction and may be a useful methodology to enhance our understanding of AF and model patient-specific disease.

Indexed as

Atrial FibrillationHeart Conduction SystemAdultHeart AtriaHeart RateHumansatrial fibrillationconduction velocityex vivoin vivorefractory periodwavelength

Identifiers

PMID36117385
PMCPMC9483613
OpenAlexW4296329000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.